Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
NPC Blog
NPC Blog
2010 Archives
2009 Archives
2008 Archives
2007 Archives
2006 Archives
Search Archives
Archives
  • December 2012 (3)
  • November 2012 (1)
  • October 2012 (1)
  • May 2012 (1)
  • December 2011 (1)
  • November 2011 (3)
  • October 2011 (4)
  • September 2011 (4)
  • August 2011 (6)
  • July 2011 (13)
  • June 2011 (8)
  • May 2011 (10)
  • April 2011 (14)
  • March 2011 (6)
  • February 2011 (2)
  • February 2010 (4)
  • January 2010 (1)
  • December 2009 (1)
  • November 2009 (1)
  • October 2009 (1)
  • September 2009 (2)
  • July 2009 (1)
  • April 2009 (1)
  • March 2009 (1)
  • February 2009 (1)
  • December 2008 (1)
  • October 2008 (1)
  • September 2008 (1)
  • August 2008 (2)
  • July 2008 (2)
  • June 2008 (4)
  • May 2008 (1)
  • April 2008 (1)
  • March 2008 (4)
  • February 2008 (1)
  • April 2007 (1)
  • December 2006 (1)
  • October 2006 (1)
  • September 2006 (1)
  • July 2006 (2)
  • June 2006 (3)
  •  

    Subscribe in a reader

    E-Alerts
    Signup to receive news and announcements from Nutra Pharma:
    First Name:
    Last Name:
    Email:
    Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.
    NPC Blog

    Nutra Pharma Provides Sales and Marketing Update

    Posted on Dec 20th, 2012 by Corporate Communications

    Nutra Pharma is providing an update on the sales and marketing efforts of TCN as they begin their global marketing campaign for Nutra Pharma’s over-the-counter (OTC) pain reliever, Nyloxin™. Coral Springs, FL. – December 20, 2012 – Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is providing updates on the sales and marketing activities of TCN, a distributor of Nutra Pharma’s over-the-counter (OTC) pain reliever, Nyloxin™. In September 2012, Nutra Pharma announced the beginning of distribution efforts by the TCN group of direct distributors. Since that time, TCN has worked diligently to introduce Nyloxin™ to approximately 40,000 distributors in the United States and almost 400,000 distributors globally. Sales to individual consumers have already begun in the US, Europe, Asia and Africa. Additionally, TCN has scheduled marketing efforts in the US that will include internet, radio and television. Read the entire press release


    SEC Disclaimer
    This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Nutra Pharma Provides Sales and Marketing Update", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


    del.icio.us:Nutra Pharma Provides Sales and Marketing Update digg:Nutra Pharma Provides Sales and Marketing Update spurl:Nutra Pharma Provides Sales and Marketing Update wists:Nutra Pharma Provides Sales and Marketing Update simpy:Nutra Pharma Provides Sales and Marketing Update newsvine:Nutra Pharma Provides Sales and Marketing Update blinklist:Nutra Pharma Provides Sales and Marketing Update furl:Nutra Pharma Provides Sales and Marketing Update reddit:Nutra Pharma Provides Sales and Marketing Update fark:Nutra Pharma Provides Sales and Marketing Update blogmarks:Nutra Pharma Provides Sales and Marketing Update Y!:Nutra Pharma Provides Sales and Marketing Update smarking:Nutra Pharma Provides Sales and Marketing Update magnolia:Nutra Pharma Provides Sales and Marketing Update segnalo:Nutra Pharma Provides Sales and Marketing Update gifttagging:Nutra Pharma Provides Sales and Marketing Update

     


    Nutra Pharma Introduces Nyloxin™ Military Strength

    Posted on Dec 19th, 2012 by Corporate Communications

    Nutra Pharma is introducing a stronger version of its over-the-counter (OTC) pain reliever, Nyloxin™, and has begun the process of registration with the United States government for sales into the military.

    Coral Springs, FL. – December 19, 2012 – Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be introducing a stronger version of its over-the-counter (OTC) pain reliever, Nyloxin™. The new product will be called Nyloxin™ Military Strength.

    Over the past few years, the U.S. Department of Defense has been reporting an increase in the use and abuse of prescription medications, particularly opiates. In 2009, close to 3.8 million prescriptions for pain relievers were written in the military. This staggering number was more than a 400% increase from the number of prescriptions written in the military in 2001. But prescription drugs are not the only issue.

    Click here to read the entire article


    SEC Disclaimer
    This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Nutra Pharma Introduces Nyloxin™ Military Strength", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


    del.icio.us:Nutra Pharma Introduces Nyloxin™ Military Strength digg:Nutra Pharma Introduces Nyloxin™ Military Strength spurl:Nutra Pharma Introduces Nyloxin™ Military Strength wists:Nutra Pharma Introduces Nyloxin™ Military Strength simpy:Nutra Pharma Introduces Nyloxin™ Military Strength newsvine:Nutra Pharma Introduces Nyloxin™ Military Strength blinklist:Nutra Pharma Introduces Nyloxin™ Military Strength furl:Nutra Pharma Introduces Nyloxin™ Military Strength reddit:Nutra Pharma Introduces Nyloxin™ Military Strength fark:Nutra Pharma Introduces Nyloxin™ Military Strength blogmarks:Nutra Pharma Introduces Nyloxin™ Military Strength Y!:Nutra Pharma Introduces Nyloxin™ Military Strength smarking:Nutra Pharma Introduces Nyloxin™ Military Strength magnolia:Nutra Pharma Introduces Nyloxin™ Military Strength segnalo:Nutra Pharma Introduces Nyloxin™ Military Strength gifttagging:Nutra Pharma Introduces Nyloxin™ Military Strength

     


    Nutra Pharma Letter to Shareholders

    Posted on Dec 18th, 2012 by Corporate Communications

    Nutra Pharma CEO, Rik J Deitsch, has published a letter to Shareholders outlining the current efforts and the future goals of the Company.

    December 18, 2012Coral Springs, Florida — Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company’s Chief Executive Officer, Rik J Deitsch, had published a Shareholder Letter on the Company’s website.

    “We have been very busy here at Nutra Pharma,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “I wanted to take this opportunity to update our shareholders and the public on the status of the Company and briefly outline our goals and expectations for the coming months,” he concluded.

    Click here to read on…


    SEC Disclaimer
    This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Nutra Pharma Letter to Shareholders", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


    del.icio.us:Nutra Pharma Letter to Shareholders digg:Nutra Pharma Letter to Shareholders spurl:Nutra Pharma Letter to Shareholders wists:Nutra Pharma Letter to Shareholders simpy:Nutra Pharma Letter to Shareholders newsvine:Nutra Pharma Letter to Shareholders blinklist:Nutra Pharma Letter to Shareholders furl:Nutra Pharma Letter to Shareholders reddit:Nutra Pharma Letter to Shareholders fark:Nutra Pharma Letter to Shareholders blogmarks:Nutra Pharma Letter to Shareholders Y!:Nutra Pharma Letter to Shareholders smarking:Nutra Pharma Letter to Shareholders magnolia:Nutra Pharma Letter to Shareholders segnalo:Nutra Pharma Letter to Shareholders gifttagging:Nutra Pharma Letter to Shareholders

     


    As Seen In USA Today World Series Preview

    Posted on Nov 12th, 2012 by Corporate Communications

    Click here to see our ad on page 25 of the special USA Today MLB World Series Preview Sports Weekly.


    SEC Disclaimer
    This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " As Seen In USA Today World Series Preview", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


    del.icio.us:As Seen In USA Today World Series Preview digg:As Seen In USA Today World Series Preview spurl:As Seen In USA Today World Series Preview wists:As Seen In USA Today World Series Preview simpy:As Seen In USA Today World Series Preview newsvine:As Seen In USA Today World Series Preview blinklist:As Seen In USA Today World Series Preview furl:As Seen In USA Today World Series Preview reddit:As Seen In USA Today World Series Preview fark:As Seen In USA Today World Series Preview blogmarks:As Seen In USA Today World Series Preview Y!:As Seen In USA Today World Series Preview smarking:As Seen In USA Today World Series Preview magnolia:As Seen In USA Today World Series Preview segnalo:As Seen In USA Today World Series Preview gifttagging:As Seen In USA Today World Series Preview

     


    Rheumatoid Arthritis Sufferer Conquers Everest.

    Posted on Oct 29th, 2012 by Rik Deitsch

    As seen in the Washington Post special ad supplement– Jeff Gottfurcht became the first rheumatoid arthritis sufferer to conquer Everest.
    He took Nyloxin with him as his pain reliever of choice.


    SEC Disclaimer
    This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Rheumatoid Arthritis Sufferer Conquers Everest.", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


    del.icio.us:Rheumatoid Arthritis Sufferer Conquers Everest. digg:Rheumatoid Arthritis Sufferer Conquers Everest. spurl:Rheumatoid Arthritis Sufferer Conquers Everest. wists:Rheumatoid Arthritis Sufferer Conquers Everest. simpy:Rheumatoid Arthritis Sufferer Conquers Everest. newsvine:Rheumatoid Arthritis Sufferer Conquers Everest. blinklist:Rheumatoid Arthritis Sufferer Conquers Everest. furl:Rheumatoid Arthritis Sufferer Conquers Everest. reddit:Rheumatoid Arthritis Sufferer Conquers Everest. fark:Rheumatoid Arthritis Sufferer Conquers Everest. blogmarks:Rheumatoid Arthritis Sufferer Conquers Everest. Y!:Rheumatoid Arthritis Sufferer Conquers Everest. smarking:Rheumatoid Arthritis Sufferer Conquers Everest. magnolia:Rheumatoid Arthritis Sufferer Conquers Everest. segnalo:Rheumatoid Arthritis Sufferer Conquers Everest. gifttagging:Rheumatoid Arthritis Sufferer Conquers Everest.

     


    Older Posts »

     
    Quick Nav
    Nyloxin // Chronic Pain Relief
    Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
     

     

     
    Recent News
     
    June 10, 2014
    Nutra Pharma Announces Contracts for Nyloxin Television Commercials


    January 07, 2014
    Nutra Pharma Announces the First Shipments and Product Delivery to MyNyloxin.com Independent Entrepreneurs


    December 02, 2013
    Nutra Pharma Finalizes Exclusive Network Marketing Distribution Agreement for Nyloxin


     
     
    Announcements
    Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
     
     
    Facebook   Twitter
     
    NPC
    Privacy Policy Code of Ethics